Raptor Pharmaceuticals Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.45%166.930.7%$1253.55m
LLYEli Lilly & Co. 0.18%311.431.1%$814.08m
BMYBristol-Myers Squibb Co. -0.73%70.771.0%$778.85m
PFEPfizer Inc. -1.10%44.080.9%$769.71m
ABBVAbbVie, Inc. 0.04%143.061.9%$735.85m
MRKMerck & Co., Inc. -0.81%86.800.7%$691.58m
AZNAstraZeneca Plc -3.07%54.581.0%$397.16m
ALNYAlnylam Pharmaceuticals, Inc. -0.95%200.788.2%$207.03m
NVSNovartis AG -1.47%76.010.2%$201.13m
GBTGlobal Blood Therapeutics, Inc. 0.03%67.995.4%$199.71m
GSKGSK Plc -2.13%29.370.3%$192.16m
NVONovo Nordisk A/S -0.40%97.920.1%$170.11m
HZNPHorizon Therapeutics Plc 0.54%62.975.4%$156.21m
SGENSeagen Inc. -0.96%139.205.7%$152.48m
SRPTSarepta Therapeutics, Inc. -2.42%108.1912.4%$128.76m

Company Profile

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.